Shriya M

Advancements in Glioblastoma Treatment: Strategies to Overcome Therapeutic Resistance

Started Aug. 9, 2024

Abstract or project description

With a survival time period of 14-16 months after diagnosis, Glioblastomas (GBM) remain as one of the deadliest forms of brain cancer. GBMs are complex tumors that arise from glial cells, the uncontrolled multiplication of these cells then build up to form a glioma, which is the cancerous tumor. When the gliomas reach a level of aggressiveness they form into GBMs. Traditional methods of therapy have remained as the standard care of treatment for treating GBMs, but as each GBM diagnosis being unique and complex than the last, traditional methods may not seem always effective. New research and therapy trials have shown immunotherapies as the most promising therapy for the future, demonstrating its large effect in the GBM treatment field. Immunotherapies such as Chimeric Antigen Receptor T-Cell therapy (CAR T-Cell), cancer vaccines, and immune checkpoint inhibitors have all shown various efforts in treating multiple forms of cancer, including GBMs. Though these treatments have not fully cured GBMs in diagnosed patients, with further trials and research it has the potential to become a future standard of care. This paper will delve into the various methods of treatment used on GBM, and look into the effectiveness of each of the treatments by addressing the successes and challenges.